OPKO Health (NASDAQ:OPK) Hits New 1-Year Low – Should You Sell?

Shares of OPKO Health, Inc. (NASDAQ:OPK) reached a new 52-week low during trading on Wednesday . The stock traded as low as $1.0950 and last traded at $1.0650, with a volume of 999750 shares traded. The stock had previously closed at $1.21.

More OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: ModeX pipeline momentum — OPKO says ModeX is advancing five clinical programs, which supports longer‑term growth potential in its biologics platform. Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs
• Positive Sentiment: MDX2301 Phase 1 progress — the company initiated and completed the first‑dose cohort of MDX2301 (tetravalent bispecific antibody targeting COVID variants), a clinical milestone that de‑risks that program’s early development. OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
• Neutral Sentiment: Q1 EPS in line — GAAP loss per share of ($0.07) matched consensus, which reduces immediate earnings surprise risk. OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst stance unchanged — Barrington Research reaffirmed a “market perform” rating, signaling no upgrade from the sell‑side after the print. Benzinga
• Negative Sentiment: Revenue miss and YoY decline — Q1 revenue of $124.2M missed consensus (~$130.5M) and was down ~17% year‑over‑year, highlighting near‑term top‑line pressure. OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Guidance below Street — OPKO set Q2 revenue guidance of $127M–$132M (below the ~$135.7M consensus) and FY revenue guidance roughly in a range that brackets but leans under some Street estimates; that trimmed near‑term upside. Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs

Analysts Set New Price Targets

Several research firms have recently commented on OPK. Barrington Research reissued a “market perform” rating on shares of OPKO Health in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OPKO Health has an average rating of “Hold” and a consensus price target of $1.55.

OPKO Health Price Performance

The firm’s fifty day moving average price is $1.18 and its 200 day moving average price is $1.28. The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. The stock has a market cap of $800.82 million, a PE ratio of -3.52 and a beta of 1.49.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. OPKO Health’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. As a group, equities analysts expect that OPKO Health, Inc. will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds have recently bought and sold shares of OPK. Goldman Sachs Group Inc. raised its stake in OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after purchasing an additional 3,600,378 shares in the last quarter. Millennium Management LLC raised its stake in OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares in the last quarter. AQR Capital Management LLC raised its stake in OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. OP Asset Management Ltd purchased a new stake in OPKO Health during the first quarter valued at $1,257,000. Finally, HRT Financial LP purchased a new stake in OPKO Health during the fourth quarter valued at $851,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.